Practice-changing potential highlighted in ACC coverage; discussion on de-escalation of therapy post-MI; social media engagement among general cardiologists.
Discontinuing beta-blockers ≥1 year post-MI was noninferior to continuation (HR 0.80; 95% CI 0.57-1.13; P=0.001 for noninferiority).
RCT
1:1
Open-label
Yes
Does discontinuation of beta-blocker therapy prevent adverse cardiovascular events compared to continuation in stable patients with LVEF ≥40% at least 1 year post-myocardial infarction?
2,540 patients stable after a myocardial infarction, with a left ventricular ejection fraction of at least 40% and no heart failure, who had received beta-blocker therapy for at least 1 year after the myocardial infarction. Mean age 63.2 years, 12.8% women. Conducted in South Korea.
Discontinuation of beta-blocker therapy
Continuation of beta-blocker therapy
Composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failurecomposite
In stable patients with LVEF ≥40% who are at least 1 year post-myocardial infarction, discontinuing beta-blocker therapy is noninferior to continuing it for preventing death, recurrent MI, or heart failure hospitalization.
BACKGROUND: The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary coronary-artery reperfusion and secondary prevention interventions. METHODS: We conducted an open-label, randomized, noninferiority trial at 25 centers in South Korea. Patients whose condition remained stable after a myocardial infarction, who had a left ventricular ejection fraction of at least 40% and no heart failure, and who had received beta-blocker therapy for at least 1 year after the myocardial infarction were randomly assigned in a 1:1 ratio to discontinue or to continue beta-blocker therapy. The primary end point was a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure. The prespecified noninferiority margin was an upper limit of the 95% confidence interval for the hazard ratio of 1.4. RESULTS: A total of 2540 patients underwent randomization; 1246 were assigned to beta-blocker discontinuation and 1294 to beta-blocker continuation. The mean age of the patients was 63.2 years, and 12.8% were women. At a median follow-up of 3.1 years (interquartile range, 2.5 to 3.5), a primary end-point event had occurred in 58 patients (4-year Kaplan-Meier estimate, 7.2%) in the discontinuation group and in 74 patients (4-year Kaplan-Meier estimate, 9.0%) in the continuation group (hazard ratio, 0.80; 95% confidence interval, 0.57 to 1.13; P = 0.001 for noninferiority). The incidence of serious adverse events was similar in the two groups. CONCLUSIONS: Among patients who received beta-blocker therapy beyond the first year after a myocardial infarction, discontinuation of beta-blocker therapy was noninferior to continuation with respect to a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure. (Funded by Patient-Centered Clinical Research Coordinating Center in the Ministry of Health and Welfare, South Korea; SMART-DECISION ClinicalTrials.gov number, NCT04769362.).
“At subsequent visits, it’s always an opportunity to revisit [and ask] can we reduce this pill burden? This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-bl...”
Building similarity graph...
Analyzing shared references across papers
Karam Choi
Danbee Kang
Weon Kim
New England Journal of Medicine
New York University
Yonsei University
Sungkyunkwan University
Building similarity graph...
Analyzing shared references across papers
Choi et al. (Mon,) conducted a rct in Myocardial infarction (n=2,540). Discontinuation of beta-blocker therapy vs. Continuation of beta-blocker therapy was evaluated on Composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure (HR 0.80, 95% CI 0.57 to 1.13, p=0.001 for noninferiority). Discontinuing beta-blockers ≥1 year post-MI was noninferior to continuation (HR 0.80; 95% CI 0.57-1.13; P=0.001 for noninferiority).
www.synapsesocial.com/papers/69ccb7c216edfba7beb89e15 — DOI: https://doi.org/10.1056/nejmoa2601005
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: